Phthalate biomarker concentrations did not result in an increased risk of developing invasive breast cancer, according to results from a prospective subgroup analysis of women enrolled in the Women’s Health Initiative (WHI).1 Although the study authors didn’t observe a large increase in invasive breast cancer risk as concentrations of phthalate biomarkers increased, they also “weren’t able…
A well-known means to differentiate between normal and malignant tumors is tissue hypoxia, and a recent study confirmed “extensive intertumor- and intratumor-type heterogeneity in tumor hypoxia” in 8006 tumors across 19 tumor types.The study authors noted “subsets of patients with a range of solid tumors with genetic instability may benefit from hypoxia-targeting therapy.”For community oncologists, study…
Dacarbazine, although once a staple of melanoma therapy, essentially has no current role in the treatment of any type or stage of melanoma.
Among 4 specific breast cancer stages, T2N1 cancers showed the highest risk for local recurrence, regional recurrence, and distant metastases within 10 years from diagnosis.
A new white paper emphasizes the benefits of germline testing.
Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.
A large, long-term study found a 97% event-free survival rate at 18 months.
The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.
The phase 3 study found the combination effective, regardless of tumor proportion score.
Most non-Hodgkin lymphomas do not display the same genetic alteration as classical Hodgkin lymphoma, and are much less susceptible to PD-1 blockade.
